Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CARBINOXAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CARBINOXAMINE MALEATE.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CARBINOXAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Category A/B
Category C
Antihistamine
Antihistamine